Figure 1.
Efficacy of ARNAX + tumor‐associated antigen (TAA) therapy depends on tumor type. A, WT EG7 (PD‐L1lo EG7)‐bearing mice were s.c. given PBS or 10 μg ARNAX‐120 and 100 μg ovalbumin (OVA) 7 d after tumor implantation. PD‐L1, programmed death ligand‐1. B, MO5‐bearing mice were s.c. given PBS or 10 μg ARNAX‐140 + OVA 10 d after tumor implantation. C, LLC‐OVA‐bearing mice were s.c. given PBS or 10 μg ARNAX‐140 + OVA 9 d after tumor implantation. A‐C, Tumor sizes were evaluated in each group. Error bars indicate means ± SEM; n = 4‐6 per group. Student's t test was carried out to analyze statistical significance; *P < .05, **P < .01, n.s., not significant. D, LLC‐OVA‐bearing mice treated as in (C) were killed 15 d after tumor implantation. Proportions of CD8+ T cells in tumors and OVA‐specific cells among intratumor CD8+ T cells were analyzed by flow cytometry. Student's t test was carried out to analyze statistical significance